Switzerland: MoonLake combines with Helix SPAC to form public biotech company

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating therapies for inflammatory skin and joint diseases, and Helix Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, have entered into a definitive business combination agreement. Upon close of the transaction, the company will be renamed “MoonLake Immunotherapeutics” and will be led…

You must be a HMI Subscriber to view this content.

Subscribe Now »